The Ideal Sequence of Hybrid Coronary Revascularization with Endoscopic Coronary Revascularization
Key facts
- Who runs it
- Jessa Hospital
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 4 people enrolled
- Started
- 9 Jan 2023
- Ended
- 9 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard hybrid coronary revascularization
- Reverse hybrid coronary revascularization
- Record updated
- 29 November 2024
- Why it stopped
- After the passing of the cardiac surgeon, the clinical trial could not be continued.
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Multivessel coronary disease, defined as ≥ 50% diameter stenosis by visual estimation in 2 or more of the three major epicardial vessels or major side branches, with at least one or more one stenosis amenable to revascularization with PCI, if the patient cannot be full revascularized by surgery for a specific reason as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if the left anterior descending artery (LAD) and left circumflex have ≥50% stenosis
- Age 18-85
- Willing and able to provide informed, written consent
Who cannot take part
- Contraindication for dual antiplatelet therapy
- Previous cardiac surgery
- Requiring renal replacement therapy
- Undergoing evaluation for organ transplantation
- Requirement for other cardiac or non-cardiac surgical procedures (e.g., valve replacement, carotid revascularization)
- Left main coronary artery disease
- ST-Elevation Myocardial Infarction (STEMI)
- Ongoing high risk non-ST-segment elevation acute coronary syndrome (ACS)
- Active bleeding more or equal to BARC 2 at time of randomisation
- Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support at the time of randomisation
- Participation in other interventional clinical trials
- Recent coronary intervention (PCI)
- Life expectancy < 1 year
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hybrid coronary revascularization (HCR), a combination of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI), has emerged as an alternative treatment for multivessel coronary artery disease patients. However, the ideal sequence (PCI or CABG) is unclear.
Read full original descriptionShow less
The overall aim of this study is to investigate the best sequence within hybrid coronary revascularization using endoscopic coronary bypass grafting (i.e., first CABG then PCI versus first PCI then CABG)
The 2 groups in the trial
- Reverse hybrid coronary revascularization (HCR)Existing treatment, for comparison
Patients will undergo reverse hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
Treatment: Reverse hybrid coronary revascularization
- Standard hybrid coronary revascularization (HCR)Existing treatment, for comparison
Patients will undergo standard hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
Treatment: Standard hybrid coronary revascularization
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Controlled Trial to Investigate the Ideal Sequence of Hybrid Coronary Revascularization with Endoscopic Coronary Revascularization
- Record updated
- 29 November 2024